<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862171</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 032</org_study_id>
    <nct_id>NCT02862171</nct_id>
  </id_info>
  <brief_title>To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women</brief_title>
  <official_title>A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <brief_summary>
    <textblock>
      A follow-on, open label trial to assess continued safety of and adherence to the
      Dapivirine(25mg) vaginal ring-004 in healthy, HIV-negative women
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gynaecological assessments including pelvic/speculum examination.</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determined dapivirine residual amounts in returned used vaginal rings and/or Measured concentrations of dapivirine in plasma and/or vaginal fluids</measure>
    <time_frame>12 months</time_frame>
    <description>To assess adherence to the use of the 25 mg Dapivirine Vaginal Ring-004 inserted at monthly intervals, in an open-label trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid and specialised laboratory testing according to a pre-specified HIV testing algorithm</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the incidence of HIV-1 seroconversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral genotype resistance testing methods</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the frequency of HIV-1 drug resistance in women who acquire HIV-1 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>Dapivirine Vaginal Ring-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring-004</intervention_name>
    <description>To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial</description>
    <arm_group_label>Dapivirine Vaginal Ring-004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women must meet all the following criteria to be eligible to enrol in the trial:

          1. Previously enrolled in the IPM 027 trial

          2. Available for all visits and consent to follow all procedures scheduled for the trial

          3. Using an effective method of contraception at the Enrolment Visit, and intending to
             use an effective contraceptive method for the duration of trial participation, unless
             post-menopausal with no history of menses for one year prior to screening

          4. HIV-negative as determined by the HIV algorithm applied at Screening/Pre- Enrolment

          5. Willing to refrain from participation in another research trial using drugs, vaccines,
             medical devices and microbicides for the duration of the IPM 032 trial

          6. Willing to provide adequate locator information for trial retention purposes and be
             reachable per local standard procedures (e.g., by home visit or telephone; or via
             family or close neighbour contacts); confidentiality to be maintained.

        Exclusion Criteria:

        Women who meet any of the following criteria are NOT eligible to enrol in the trial:

          1. Investigational product use permanently discontinued in response to an AE (where the
             AE was considered related to investigational product) or safety-related concern while
             taking part in the IPM 027 trial

          2. Participant self-report of taking post-exposure prophylaxis (PEP) within â‰¤ 2 months at
             Screening Visit Note: Participants may be enrolled after completing the PEP regimen
             and a negative HIV test was documented at least 2 months prior to screening for IPM
             032

          3. Currently pregnant, intends to become pregnant or currently breast-feeding

          4. Known drug abuse or alcohol dependence in the 12 months prior to screening

          5. Participated in another research trial (other than IPM 027) using drugs, medical
             devices, microbicides or oral pre-exposure prophylaxis agents within 30 days prior to
             screening

          6. Any new illness or condition(s), chronic condition(s) or abnormal laboratory
             finding(s) that, in the opinion of the investigator, might put the participant at
             risk, or interfere with the trial objectives or the participant's adherence to trial
             requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Annalene Nel</last_name>
    <phone>301-608-2221</phone>
    <phone_ext>201</phone_ext>
    <email>anel@ipmglobal.org.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>Madibeng Centre for Research</name>
      <address>
        <city>Brits</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Louw</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Desmond Tutu HIV Foundation</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Gill</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ndlovu Medical Centre</name>
      <address>
        <city>Elandsdoorn</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Moraba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qhakaza Mbokodo</name>
      <address>
        <city>Ladysmith</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Kotze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MatCH Edendale Research Center</name>
      <address>
        <city>Pietermaritzburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thando Gwetu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MRC/UVRI Uganda Research Unit on AIDS</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Kusumererwa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

